Approved Oncology Deal Benchmarks
Market Analysis
Approved oncology licensing deals carry a median total deal value of $5.7B, with upfront payments ranging from $1.5B to $2.5B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 37% to upfront and 63% to milestones.
The oncology landscape at the approved stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $180M, regulatory milestones contribute $898M, and commercial milestones reach $2.5B. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.
Royalty rates for approved oncology deals range from 19.3% to 30% at the base tier, with high-tier escalation to 34%. The reduced risk profile at this stage justifies higher fixed royalty commitments.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for approved oncology deals?
How are approved oncology deal milestones structured?
What royalty rates are typical for approved oncology licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.